Is the Cholesteryl Ester Transfer Protein Proatherogenic or Antiatherogenic in Humans?**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 50, Issue 20, 2007, Pages 1956-1958

  Cuchel, Marina ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER TRIACYLGLYCEROL LIPASE; TORCETRAPIB;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; EDITORIAL; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR;

ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS; MYOCARDIAL INFARCTION;

EID: 35748971491     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.07.059     Document Type: Editorial

References (22)

1. Cholesterol: the good, the bad, and the stopped trials. Lancet 368 (2006) 2034
2. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
3. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
4. Tall A.R. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 356 (2007) 1364-1366
5. Schwartz C.C., VandenBroek J.M., and Cooper P.S. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 45 (2004) 1594-1607
6. Tanigawa H., Billheimer J.T., Tohyama J.-I., Zhang Y., Rothblat G., and Rader D.J. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation 116 (2007) 1267-1273
7. Lewis G.F., and Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 (2005) 1221-1232
8. Hirano K., Yamashita S., Nakajima N., et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17 (1997) 1053-1059
9. Moriyama Y., Okamura T., Inazu A., et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 27 (1998) 659-667
10. Tall A.R., Yvan-Charvet L., and Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 27 (2007) 257-260
11. Wolfe M.L., and Rader D.J. Cholesteryl ester transfer protein and coronary artery disease: an observation with therapeutic implications. Circulation 110 (2004) 1338-1340
12. Zhuang Y., Wang J., Qiang H., et al. Cholesteryl ester transfer protein levels and gene deficiency in Chinese patients with cardio-cerebrovascular diseases. Chin Med J (Engl) 115 (2002) 371-374
13. Klerkx A.H., de Grooth G.J., Zwinderman A.H., Jukema J.W., Kuivenhoven J.A., and Kastelein J.J. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 34 (2004) 21-28
14. de Grooth G.J., Smilde T.J., Van Wissen S., et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 173 (2004) 261-267
15. Boekholdt S.M., Kuivenhoven J.A., Wareham N.J., et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation Into Cancer and Nutrition)-Norfolk population study. Circulation 110 (2004) 1418-1423
16. Goto A., Sasai K., Suzuki S., et al. Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography. Atherosclerosis 159 (2001) 153-163
17. Borggreve S.E., Hillege H.L., Wolffenbuttel B.H., et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 91 (2006) 3382-3388
18. Marschang P., Sandhofer A., Ritsch A., Fiser I., Kvas E., and Patsch J.R. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med 260 (2006) 151-159
19. Borggreve S.E., Hillege H.L., Dallinga-Thie G.M., et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J 28 (2007) 1012-1018
20. Hibino T., Sakuma N., and Sato T. Higher level of plasma cholesteryl ester transfer activity from high-density lipoprotein to apo B-containing lipoproteins in subjects with angiographically detectable coronary artery disease. Clin Cardiol 19 (1996) 483-486
21. de Vries R., Perton F.G., Dallinga-Thie G.M., et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 54 (2005) 3554-3559
22. Zeller M., Masson D., Farnier M., et al. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol 50 (2007) 1948-1955